Bio-Rad Laboratories Lowers FY2026 Sales Guidance from $2.596B-$2.622B to $2.506B-$2.596B vs $2.630B Est

Benzinga Newsdesk www.benzinga.com Negative 95.7%

Neg 95.7% Neu 0% Pos 0%

Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.596 billion-$2.622 billion to $2.506 billion-$2.596 billion vs $2.630 billion estimate.